Project Description

Understanding Implications of Proposed Best Price Revisions for Manufacturer Assistance Programs

Deborah Stoll, A MM&M Digital Publication
Jason Zemcik, Senior Director, Product Management
Rick Fry, Senior Vice President, Commercial Solutions

ABSTRACT

On June 17, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that, if finalized, would revise how manufacturer coupons are accounted for in best price calculations.

As a co-pay program provider, TrialCard believes this will have a negative effect on a biopharmaceutical manufacturer’s ability to deliver much-needed patient assistance for high-cost specialty medications, many of which do not have generic alternatives. View this e-book for more insights.

Please submit the form below to view this resource.

Request Resource